Trevi Therapeutics, Inc. (TRVI)
| Market Cap | 175.16M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -29.07M |
| Shares Out | 68.96M |
| EPS (ttm) | -0.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 169,812 |
| Open | 2.630 |
| Previous Close | 2.650 |
| Day's Range | 2.450 - 2.680 |
| 52-Week Range | 0.970 - 4.000 |
| Beta | 0.87 |
| Analysts | Strong Buy |
| Price Target | 8.50 (+234.65%) |
| Earnings Date | May 9, 2024 |
About TRVI
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Ref... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for TRVI stock is "Strong Buy." The 12-month stock price forecast is $8.5, which is an increase of 234.65% from the latest price.
News
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
Professor Jacky Smith will present on the reduction of cough bouts with nalbuphine ER observed in patients with IPF in the CANAL trial NEW HAVEN, Conn. , April 9, 2024 /PRNewswire/ -- Trevi Therapeuti...
Trevi Therapeutics to Participate in Upcoming April Events
NEW HAVEN, Conn. , April 4, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine E...
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
Margaret Garin, MD, MSCR, joins team to advance the development of Haduvio in chronic cough indications NEW HAVEN, Conn. , April 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a cli...
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
Reaffirms guidance for the Phase 2a RIVER trial of Haduvio in RCC patients with topline data expected in the second half of 2024 Enrollment progressing in the Phase 2b CORAL dose-ranging trial of Ha...
Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn.
Trevi Therapeutics to Participate in Upcoming March Events
NEW HAVEN, Conn. , Feb. 28, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER...
Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Corporate presentation will be held on Wednesday, February 14, 2024, at 10:00 a.m. ET NEW HAVEN, Conn.
Trevi Therapeutics Provides Business Updates
NEW HAVEN, Conn. , Jan. 4, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER...
Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)
Expect to enroll approximately 160 subjects and study 3 doses of Haduvio against placebo Primary efficacy endpoint is the relative change in 24-hour cough frequency of Haduvio versus placebo NEW HAVEN...
Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update
Initiated Phase 2a RIVER trial of Haduvio in refractory chronic cough (RCC) patients and expect topline data in the second half of 2024 Expect to initiate Phase 2b dose-ranging trial of Haduvio for th...
Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio™ for Refractory Chronic Cough
Expect to enroll 60 subjects across a broad range of cough frequencies RIVER topline data expected in the second half of 2024 NEW HAVEN, Conn. , Nov. 2, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (...
Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023
Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn.
Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio™ in Prurigo Nodularis
Continued reduction in WI-NRS observed among participants who remained in the study through 52 weeks of treatment Safety data over 52 weeks: treatment was well tolerated and consistent with 14-week bl...
Trevi Therapeutics to Participate in Upcoming September Events
NEW HAVEN, Conn. , Sept. 6, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER...
Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update
Plans to initiate three clinical studies in chronic cough indications for later this year remain on track Data from Phase 2 CANAL trial of chronic cough in patients with idiopathic pulmonary fibrosis ...
Trevi Therapeutics to Report Q2 2023 Financial Results and Provide a Corporate Update on August 10, 2023
Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn.
Trevi Therapeutics to Participate in Upcoming August Events
NEW HAVEN, Conn. , Aug. 1, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER)...
Trevi Therapeutics to Participate in Upcoming July Investor Events
NEW HAVEN, Conn. , July 6, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER)...
Trevi Therapeutics to Participate in Upcoming June Conferences
Dr. Toby Maher will be presenting data results from the Phase 2 CANAL trial in IPF chronic cough at American Cough Conference NEW HAVEN, Conn. , May 30, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (...
Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial in IPF Chronic Cough in NEJM Evidence
Nalbuphine ER resulted in a rapid and marked reduction in recorded daytime cough among patients suffering from IPF-related cough The mean change in 24-hour objective cough frequency was similar in pat...
Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update
I nitiating three clinical studies in chronic cough indications later this year Received Notice of Allowance for key U.S. patent for the use of oral nalbuphine ER for the treatment of chronic cough in...
Trevi Therapeutics to Present at Upcoming Yale Innovation Summit 2023
Presentation to take place on June 1 from 10:30 a.m. to 12:00 p.m.
Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023
Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn.
Trevi Therapeutics Announces Two Presentations on the Phase 2 CANAL Data at the ATS 2023 International Conference
Dr. Toby Maher of the Keck School of Medicine will give oral presentations for both scientific abstracts on oral nalbuphine extended release for chronic cough in IPF NEW HAVEN, Conn. , May 2, 2023 /PR...
Trevi Therapeutics to Participate in Upcoming May Investor Events
2023 Aegis Virtual Conference, May 2-4 American Thoracic Society's (ATS) 2023 Respiratory Innovation Summit (RIS), May 19-20 Yale Innovation Summit, May 31-June 1 NEW HAVEN, Conn. , April 27, 2023 /PR...